Propanc Biopharma (PPCB) Return on Capital Employed (2012 - 2025)
Propanc Biopharma (PPCB) posted quarterly Return on Capital Employed of 503.9% for Q4 2025, down 53292.0% year-over-year from N/an in Q4 2024, and down 24.47% quarter-over-quarter from 404.83% in Q3 2025.
Propanc Biopharma (PPCB) Return on Capital Employed (2012 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Return on Capital Employed for 14 consecutive years, with 503.9% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Capital Employed fell 53292.0% year-over-year to 503.9%; the TTM figure through Dec 2025 stood at 503.9% (down 53292.0% YoY), while the FY2025 annual figure was 1340.2%, down 138142.0% from the prior year.
- Return on Capital Employed retreated to 503.9% in Q4 2025 per PPCB's latest filing, from 404.83% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 82.15% in Q3 2021 and bottomed at 774.12% in Q1 2025.
- Historically, Return on Capital Employed has averaged 55.92% across 5 years, with a median of 54.92% in 2021.
- Annual changes were most pronounced in 2021 — Return on Capital Employed surged 1743 bps — and 2025, when it sank 81599 bps.
- Propanc Biopharma's Return on Capital Employed stood at 69.2% in 2021, then grew by 14 bps to 78.93% in 2022, then plunged by 48 bps to 40.86% in 2023, then decreased by 29 bps to 29.02% in 2024, then tumbled by 1837 bps to 503.9% in 2025.
- Business Quant data shows PPCB's Return on Capital Employed at 503.9% in Q4 2025, 404.83% in Q3 2025, and 369.5% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | -503.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -503.90% |
| Sep 30, 2025 | -404.83% |
| Jun 30, 2025 | -369.50% |
| Mar 31, 2025 | -774.12% |
| Dec 31, 2024 | 29.02% |
| Sep 30, 2024 | 34.95% |
| Jun 30, 2024 | 41.09% |
| Mar 31, 2024 | 41.87% |
| Dec 31, 2023 | 40.86% |
| Sep 30, 2023 | 53.81% |
| Jun 30, 2023 | 58.13% |
| Mar 31, 2023 | 73.82% |
| Dec 31, 2022 | 78.93% |
| Sep 30, 2022 | 75.98% |
| Jun 30, 2022 | 67.78% |
| Mar 31, 2022 | 71.16% |
| Dec 31, 2021 | 69.20% |
| Sep 30, 2021 | 82.15% |
| Jun 30, 2021 | 59.22% |
| Mar 31, 2021 | 56.02% |